Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

Bioorganic & Medicinal Chemistry
2017.0

Abstract

The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of clinically acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC). New derivatives of 4(3H)-quinazolinones were synthesized and evaluated for their inhibitory activity against NSCLC. The results of the study demonstrated that compound 79, 7-chloro-3-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one was found to be the most potent compounds of the series with IC50 value of 0.031μM against mutant T790M/L858R EGFR. Compounds 15, 51, 73, 75, 78, 79 and 96 were less potent against A549 (WT EGFR and k-Ras mutation) and HT-29 (non-special gene type) cells, showing a high safety index. The obtained results showed that compounds 15, 51, 73, 75, 78, 79 and 96 could be the promising template to overcome drug resistance mediated by the EGFR T790 Mutant.

DOI： 10.1016/j.bmc.2017.03.039

Knowledge Graph

Similar Paper

Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle
Bioorganic & Medicinal Chemistry 2017.0
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine<sup>790</sup> → Methionine<sup>790</sup> Mutant
Journal of Medicinal Chemistry 2012.0
Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines
European Journal of Medicinal Chemistry 2016.0
Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant
MedChemComm 2012.0
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant
Bioorganic &amp; Medicinal Chemistry 2016.0
Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines
Bioorganic &amp; Medicinal Chemistry Letters 2021.0
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives
Bioorganic &amp; Medicinal Chemistry 2016.0
6-Oxooxazolidine–quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR
Bioorganic &amp; Medicinal Chemistry 2016.0
Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors
European Journal of Medicinal Chemistry 2018.0
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2016.0